Ken Griffin Regeneron Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1024.09 - $1201.76 $63.4 Million - $74.4 Million	61,900 Added 74.13%	145,400 $153 Million
Q2 2024 Aug 14, 2024	SELL	$883.2 - $1071.19 $34.8 Million - $42.2 Million	-39,400 Reduced 32.06%	83,500 $87.8 Million
Q1 2024 May 15, 2024	SELL	$902.69 - $993.35 $107 Million - $118 Million	-118,500 Reduced 49.09%	122,900 $118 Million
Q4 2023 Feb 14, 2024	SELL	$775.18 - $881.7 $13.3 Million - $15.1 Million	-17,100 Reduced 6.62%	241,400 $212 Million
Q3 2023 Nov 14, 2023	SELL	$692.45 - $844.37 $29.7 Million - $36.2 Million	-42,900 Reduced 14.23%	258,500 $213 Million
Q2 2023 Aug 14, 2023	SELL	$700.03 - $830.35 $108 Million - $128 Million	-154,600 Reduced 33.9%	301,400 $217 Million
Q1 2023 May 15, 2023	BUY	$680.49 - $826.97 $50.5 Million - $61.4 Million	74,200 Added 19.43%	456,000 $375 Million
Q4 2022 Feb 14, 2023	SELL	$705.89 - $766.39 $64.8 Million - $70.4 Million	-91,800 Reduced 19.38%	381,800 $275 Million
Q3 2022 Nov 14, 2022	BUY	$573.97 - $724.32 $116 Million - $147 Million	202,400 Added 74.63%	473,600 $326 Million

1,531

84.1M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $79.1B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.